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Interstitial fibrosis and tubular atrophy (IFTA) is
found in approximately 25% of 1-year biopsies post-
transplant. It is known that IFTA correlates with
decreased graft survival when histological evidence
of inflammation is present. Identifying the mechanis-
tic etiology of IFTA is important to understanding
why long-term graft survival has not changed as
expected despite improved immunosuppression and
dramatically reduced rates of clinical acute rejection
(AR) (Services UDoHaH. http://www.ustransplant.org/
annual_reports/current/509a_ki.htm). Gene expres-
sion profiles of 234 graft biopsy samples were
obtained with matching clinical and outcome data.
Eighty-one IFTA biopsies were divided into subphe-
notypes by degree of histological inflammation: IFTA
with AR, IFTA with inflammation, and IFTA without
inflammation. Samples with AR (n = 54) and nor-
mally functioning transplants (TX; n = 99) were used
in comparisons. A novel analysis using gene coex-
pression networks revealed that all IFTA phenotypes
were strongly enriched for dysregulated gene path-
ways and these were shared with the biopsy profiles
of AR, including IFTA samples without histological
evidence of inflammation. Thus, by molecular profil-
ing we demonstrate that most IFTA samples have
ongoing immune-mediated injury or chronic rejec-
tion that is more sensitively detected by gene
expression profiling. These molecular biopsy profiles
correlated with future graft loss in IFTA samples
without inflammation.
Abbreviations: ABMR, antibody-mediated rejection;
ANOVA, analysis of variance; AR, clinical acute rejec-
tion; DEG, differentially expressed gene; dnDSA,
de novo donor-specific antibody; DSA, donor-specific
antibody; FC, fold change; FDR, false discovery rate;
GCN, gene coexpression network; GEO, Gene Expres-
sion Omnibus; HLA, human leukocyte antigen; IFN-c,
interferon-gamma; IFTA, interstitial fibrosis and tubu-
lar atrophy; N/A, not applicable; subAR, subclinical
acute rejection; TCMR, T cell–mediated rejection; TX,
Treatment group with excellent functioning kidney
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Introduction
Interstitial fibrosis and tubular atrophy (IFTA) describes a
common histological abnormality seen in kidney trans-
plant biopsies in which normal cortical structures are
replaced by interstitial fibrosis. IFTA, when accompanied
by histological evidence of inflammation, correlates with
decreased graft survival (1–3). IFTA is evident histologically
in 25% or more of 1-year surveillance biopsies despite
concomitant stable renal function (4,5). Identifying the
etiologic mechanisms of IFTA is important to better
understand why 10-year graft survival has not improved
significantly despite improved immunosuppression proto-
cols and a dramatic decrease in the incidence of clinical
acute rejection (AR) (6–8).
1982
© Copyright 2016 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/ajt.13728
American Journal of Transplantation 2016; 16: 1982–1998
Wiley Periodicals Inc.
Acute T cell–mediated rejection (TCMR), presenting as
either AR or subclinical acute rejection (subAR, histologi-
cal AR without graft dysfunction only demonstrated by
surveillance biopsies), is clearly linked to a higher risk of
IFTA (3,9,10). In a study of 797 recipients, early episodes
of AR led to more fibrosis and inflammation in 1- and
2-year protocol biopsies than those without an occur-
rence of AR. AR episodes followed by abnormal histol-
ogy also resulted in reduced graft survival (9). Likewise,
subAR also increases the risks of developing IFTA and
graft loss and occurs in as many as 20% of surveillance
biopsies done in the first year posttransplant (1,11–15).
Given these strong associations of AR and subAR with
the future development of IFTA, we questioned whether
IFTA biopsies contained unrecognized cellular rejection.
In our model, IFTA marks chronically uncontrolled rejec-
tion, and its development may associate with a higher
risk of graft failure.
We performed gene expression profiling on 234 kidney
graft biopsies obtained for both surveillance and cause
from over 1000 patients at seven transplant centers with
matching clinical and outcome data. Eighty-one samples
were given a diagnosis of IFTA, in which there was his-
tological evidence of IFTA without a clear etiology
(i.e. BK nephropathy or recurrent glomerulonephritis).
These IFTA samples were then classified into subpheno-
types based on the degree of inflammation identified on
light histology, including IFTA with concomitant acute
rejection (IFTA with AR; n = 29), IFTA with inflammation
(n = 10), and IFTA without inflammation (n = 42). Sam-
ples with biopsy-proven AR (n = 54) and normally func-
tioning transplants (TX; n = 99) were included for
comparison. Confirmatory outcome data were obtained
by data query to the United Network for Organ Sharing.
The gene expression results were validated using a pub-
lished dataset derived from an independent, external
cohort of late biopsies (Gene Expression Omnibus
[GEO]; GSE21374) (16,17).
By molecular biopsy profiling we found that differential
gene expression in all IFTA phenotypes was strongly
enriched for the same dysregulated gene profiles seen in
AR biopsies. All IFTA phenotypes (n = 81) demonstrated
as much as 81% commonality in differentially expressed
genes with AR, and a strong enrichment for AR immune/
inflammatory and metabolic/tissue integrity molecular
pathways. This finding was true even for IFTA samples
without any histological evidence of inflammation
(n = 42), a group currently thought to be low risk for
graft loss. Thus, molecular profiling indicated that most
IFTA samples have ongoing and often subclinical
immune-mediated injury that is more sensitively detected
with gene expression profiling than by light histology.
Furthermore, in IFTA samples without histological evi-
dence of inflammation, we found that the relative
expression of AR-affiliated genes correlated with a higher
risk of graft loss at 5 or more years.
Methods
Study population
Two hundred thirty-four kidney allograft biopsies were collected as part
of an National Institutes of Health–funded Transplant Genomics Collabora-
tive Group from 2005 to 2011 by protocol or “for cause” from 210
patients from seven clinical centers. More than one biopsy from the
same patient was included only if there was a change in pathology. The
only exclusions were biopsies that did not conform to the study’s
inclusion/exclusion criteria (Appendix S1), such as a diagnosis of BK
nephritis or recurrent glomerulonephritis (n = 5). Each biopsy was
reviewed locally as well as by a blinded central pathologist (LG) with no
clinical information provided. When there was a discrepancy between the
two reports, the senior investigator (DRS) reviewed the histology slides
and reached a conclusion including discussion and agreement with the
pathologists as necessary. The phenotypes were defined as follows: AR
is biopsy-proven TCMR with a rising serum creatinine; IFTA with inflam-
mation is Banff IFTA+i; IFTA with AR are cases where local and central
pathology reviews called both present and TX are controls based on
surveillance biopsies done from 1 to 2 years. Institutional review boards
approved all research protocols.
Analysis of phenotypic data
ANOVA and chi-squared tests were used to detect differences in continu-
ous and categorical variables between phenotypes and p-values were
adjusted with Bonferroni correction for multiple hypothesis testing. Less
than 1% of the phenotypic features were missing. Survival curve analysis
was performed on death-censored data using JMP software (SAS, Cary,
NC) and Wilcoxon’s ranked tests. Hazard ratios for clinical phenotypic
characteristics were calculated using a Cox proportional hazards model
adjusting for multiple clinical variables: age, sex, race/ethnicity, time post-
transplant, C4d, donor age, BMI, and phenotypes (see Results and
Appendix S2).
Differential gene expression and pathway mapping
Microarray protocols are in Appendix S1 and array data is available online
(NCBI’s Gene Expression Omnibus database; http://www.ncbi.nlm.nih.-
gov/geo/; Accession number GSE GSE76882). Differentially expressed
genes (DEGs) between phenotypes were determined by two-sample
t-tests with False Discovery Rates (FDRs) calculated using the method of
Storey et al (18) to account for multiple hypothesis testing. Immune
pathway mapping and gene set enrichment for biological processes were
performed using gene ontology (GO) and Ingenuity Pathway Analysis. To
avoid false-positive enrichment based on cell type, kidney gene
expression (as found in our biopsy dataset) was used as the background
gene set.
Gene Coexpression Network Analysis
By having gene expression profiles for many samples, we can look for
pairs of genes that demonstrate a similar expression pattern across sam-
ples (two genes in which the transcript levels rise and fall together
across the samples). These two genes are called “coexpressed genes.”
Gene coexpression is of biological interest since it suggests a relationship
among coexpressed genes. A gene coexpression network (GCN) is sim-
ply an undirected graph where each node corresponds to a gene, and
each gene is linked to other genes by an edge if there exists a statisti-
cally significant coexpression. GCNs do not attempt to infer a causal
relationship between genes and the edges represent only a correlation in
gene expression across samples.
GCNs can separate groups of similar-behaving (and likely to be
biologically related) genes from a larger gene set, and do so without the
introduction of user bias when groups of genes are identified based on
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investigator interpretations of external data and immune paradigms.
Thus, these groups of genes or GCNs help identify related genes with a
specific function within the framework of a larger biological process (e.g.
coexpressed immunoglobulin genes within a large set of genes
differentially expressed in AR). In this study, we built GCNs from IFTA
and AR differentially expressed genes, and thus delineated the biological
processes that define these phenotypes. The mathematical model and
full explanation for GCN construction is outlined in Appendix S1,
Section 4.
Results
Patient characteristics and outcomes
A total of 234 biopsies (114 surveillance, 120 “for cause”)
comprise this retrospective study (54 AR, 42 IFTA without
inflammation, 10 IFTA with inflammation, 29 IFTA with AR,
and 99 TX; Table 1). Twenty-one of the participants had
two biopsies analyzed, but the biopsies were taken at
Table 1: Demographics and outcomes of 210 participants grouped by histological phenotypes
AR
IFTA without






Age (mean  SE) 39  2 40  2 35  3 41  5 41  2 0.8
Female2 22 (47%) 23 (58%) 12 (43%) 5 (50%) 37 (47%) 0.61
Black 2 (4%) 5 (13%) 1 (4%) 0 4 (5%) 0.39
Recipients
Total number of patients 50 40 28 10 82 N/A
Total number of biopsies 54 42 29 10 99 N/A
IFTA Grade (Banff)2 1/2/3 N/A 18/16/6 9/8/5 4/4/0 N/A 0.67
Protocol biopsy 2/50 (4%) 13/40 (33%) 1/28 (4%) 3/10 (30%) 72/82 (88%) <0.0001
Age (mean  SE) 46  2 44  2 40  3 49  5 50  2 0.02
Female 15 (30%) 19 (48%) 12 (43%) 3 (30%) 28 (34%) 0.55
African American 6 (12%) 4 (10%) 5 (18%) 1 (10%) 6 (7%) 0.64
Diabetes2 5 (10%) 4 (11%) 3 (11%) 2 (20%) 11 (13%) 0.91
Deceased donor2 30 (60%) 24 (62%) 16 (64%) 7 (78%) 43 (52%) 0.57
HLA mm (mean  SE)3 3.8  0.3 3.3  0.3 3.1  0.4 3.7  0.7 3.6  0.2 0.54
PRA ≥ 202 11 (22%) 8 (22%) 4 (17%) 1 (13%) 11 (13%) 0.77
Induction therapy4 42 (84%) 34 (85%) 25 (89%) 10 (100%) 62 (76%) 0.24
C4d positive 11 (22%) 2 (5%) 5 (18%) 1 (10%) 1 (1%) <0.0001
Borderline or suspicious
for acute cellular rejection
(according to local pathologist)
N.A. 14 (33%) N.A. 6 (60%) 2 (2%) <0.0001













Biopsy >12 months 27 (54%) 34 (85%) 27 (96%) 6 (60%) 60 (73%) <0.0001
Death-censored graft loss 15 (32%) 14 (35%) 11 (38%) 3 (30%) 0 N/A
Time to death-censored graft loss 1450  334 2935  346 2747  390 1708  747 N.A. 0.015
Time from biopsy to graft loss 665  183 452  189 678  213 412  408 N.A. 0.78
Death 12 (24%) 6 (15%) 2 (7%) 1 (10%) 3 (4%) N/A
Time to death 1304  273 1813  385 1417  667 1324  944 1549  408 0.87
Clinical center enrollment
CCF 9 (18%) 5 (12.5%) 2 (7%) 2 (20%) 12 (15%) N/A
SGH 10 (20%) 7 (17.5%) 2 (7%) 2 (20%) 48 (58%) N/A
SVMC 20 (40%) 14 (35%) 15 (54%) 4 (40%) 2 (2%) N/A
MC 1 (2%) 5 (12.5%) 0 2 (20%) 14 (17%) N/A
UCHSC 6 (12%) 7 (17.5%) 5 (18%) 0 3 (4%) N/A
UM 1 (2%) 2 (5%) 4 (14%) 0 0 N/A
NU 3 (6%) 0 0 0 3 (4%) N/A
AR, acute rejection; CCF, Cleveland Clinic Foundation; HLA, human leukocyte antigen; IFTA, interstitial fibrosis and tubular atrophy;
MC, Mayo Clinic, Phoenix; mm, mismatch; N/A, not applicable; PRA, panel reactive antibody; SE, standard error; SGH, Scripps Green
Hospital; SVMC, Saint Vincent’s Medical Center, Los Angeles; TX, Treatment group with excellent functioning kidney; UCHSC, Univer-
sity of Colorado Health Sciences Center; UM, University of Michigan; NU, Northwestern University.
1Analysis method: analysis of variance for quantitative data (probability > F statistic), Pearson’s chi-squared test for dichotomous data.
Significant intergroup comparisons found in Appendix S2.
2Missing data: 9 (3%) diabetes, 5 (2%) donor sex, 6 (2%) donor race, 27 (10%) PRA studies, 11 (4%) deceased donor, IFTA grade 4
(5%).
3Typed HLA antigens: HLA-A1, HLA-A2, HLA-B1, HLA-B2, HLA-DR1, HLA-DR2.
4Induction therapy includes the following: anti-thymocyte globulin (Thymoglobulin), muromonab-CD3 (OKT3), basiliximab (Simulect),
daclizumab (Zenapax), and alemtuzumab (Campath).
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different time points and demonstrated a change in pathol-
ogy. Only the phenotype at the time of most recent biopsy
was used to calculate survival analysis. Thirty-three (44%)
of all IFTA samples were classified as mild (Banff Grade 1:
IFTA without inflammation = 45%; IFTA+AR = 41%;
IFTA+i = 50%). Twenty-eight (40%) of IFTA samples were
classified as moderate (Grade 2; IFTA without inflamma-
tion = 40%; IFTA+AR = 36%; IFTA+i = 50%). The remain-
ing 11 (16%) were classified as severe IFTA (Grade 3).
There were no differences in IFTA grades by subgroups
(p = 0.67).
Median follow-up time was 1613 days posttransplant
(4.4 years). Only one patient was lost to follow-up.
There were no differences in age, sex, % African
American, % diabetics, number of HLA mismatches, or
% deceased donors across phenotypes. There were a
total of 24 deaths, but no significant differences in
mortality in the “non-TX” groups according to survival
analyses.
Median time to biopsy was 420 days (374 and 1200 days
for surveillance and “for cause,” respectively). The times
to biopsy were significantly greater for AR (800  164),
IFTA without inflammation (1796  178), IFTA with
inflammation (1008  356), and IFTA with AR
(2121  213) when compared to the TX phenotype
(603  127 days) (p < 0.0001). In over half of the sub-
jects with AR, onset was >12 months posttransplant.
After censoring death, 43/210 (20%) had graft loss with a
median time of 1885 days (5.2 years; 43–9302 days).
Graft survival was significantly lower in subjects with AR,
IFTA with AR, IFTA with inflammation, and IFTA without
inflammation in comparison to TX (Figure 1). Despite dif-
ferences in graft loss risk, times from biopsy to graft loss
Figure 1: Graft survival according to histological phenotype. Interstitial fibrosis and tubular atrophy (IFTA) samples were classified
into three subphenotypes according to the degree of inflammation: IFTA plus clinical acute rejection (AR), IFTA with inflammation, and
IFTA without inflammation. Biopsies with only AR and normally functioning transplants (TX) were used for survival comparisons. The
figure shows graft survival according to these phenotypes in days posttransplant. The insert table shows the number of subjects at
key time points by phenotypes.
Table 2: Shared differentially expressed transcripts between IFTA subphenotypes (IFTA plus AR, IFTA with inflammation, and IFTA












Number of DEGs 4705 3280 1513 6229
Number (%) shared with cAR differentially
expressed transcript list
3817 (81%) 2610 (80%) 1040 (69%) 4466 (72%)
AR, acute rejection; cAR, clinical acute rejection; DEGs, differentially expressed genes; IFTA, interstitial fibrosis and tubular atrophy;
FC, fold-change; FDR, false discovery rate.
1In comparison of AR samples to patients with normal, well-functioning transplants (control; TX), there were 5345 differentially
expressed transcripts (FDR*<0.05; FC*>1.2). This table shows the large number and percent of gene transcripts shared between cAR
and each IFTA subphenotype.
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did not significantly differ by phenotype: IFTA with
inflammation (412 days), IFTA without inflammation
(452 days), AR (665 days), and IFTA with AR (678 days)
(p = 0.78).
A Cox proportional hazards model was also used to
examine the effect of various clinical variables on survival
times. We created a model including the following vari-
ables: time from transplant to biopsy, phenotype, age,
sex, black race, diabetes, C4d status, and donor age
(Appendix S2, Section 1). Of these variables, only days
from transplant to biopsy (p < 0.0001), phenotype
(p < 0.0001), and recipient age (p = 0.04) were found to
be statistically significant. We then adjusted the above
survival curves for age and time of biopsy posttransplant
using a Stratified Cox model. In the adjusted model, both
AR and IFTA phenotypes showed the same results of
equally poor long-term graft survival rates (Appendix S2,
Section 2).
A majority (n = 84; 71%) of the “for cause” biopsies and
a minority (n = 21; 19%) of the protocol biopsies had
C4d staining performed. There was no difference in
death-censored graft survival between those with posi-
tive versus negative C4d staining (p = 0.3). The calcu-
lated Cox hazard ratios for C4d positivity versus
negativity were not statistically significant (CI: 0.58–4.2)
(Appendix S2, Section 1). The majority of the samples
with future graft loss were C4d negative (74%). We do
not have donor-specific antibody (DSA) data. These biop-




Figure 2: Differentially expressed genes shared between IFTA and AR. (A) Venn diagram showing differentially expressed genes
(DEGs) shared between interstitial fibrosis and tubular atrophy (IFTA) without inflammation and clinical acute rejection (AR). (B) Plots
the differential fold changes in gene expression (DEGs) comparing IFTA without inflammation versus AR. A linear regression line and
R2 statistic demonstrates a highly concordant direction of gene expression between phenotypes; (C) and (D) repeat and validate the
analysis using an independent, external dataset. Note 1: Differentially expressed genes and fold changes are calculated in relation to
normal transplants (TX) defined by stable function and light histology. Note 2: The subphenotypes of IFTA with and without inflamma-
tion were not available for the external data set.
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Table 3: IFTA without inflammation differentially expressed genes (DEGs) (threshold FDR<0.05) ranked by absolute fold change are
shared with AR1





IGHC 2.7–10.8 Ig heavy chain production Tissue (19,20) 6 Indicates immunoglobulin producing
allograft infiltrating B cells
IGLC (9)1 2.6–7.1 Ig light chain production Tissue (19,20) 5 Indicates immunoglobulin producing
allograft infiltrating B cells
LTF 6.1 Innate anti-microbial,
inflammation-related
Tissue (16,20–24) 1 Literature review connects with kidney
injury and #1 AR gene, which links
AR and IFTA to injury
IGJ 5.9 Ig linker protein Tissue (20) 12 Indicates Immunoglobulin producing
allograft infiltrating B cells
ALB 4.1 Main protein in blood, carrier
protein for steroids, fatty
acids and hormones.
Tissue (25) 8 Previously showed to be decreased in
AR (25) and kidney injury, (35) likely
reflects metabolic disturbance.
SERPINA3 4.0 Protease inhibitor, cleaves
PMN cathepsin G and MC
chymase
Tissue (16,23,24,26,27) 3 Literature review associates with
kidney injury and cell turnover. As
the #3 AR gene, connects AR and
IFTA to injury
CXCL6 3.5 Interacts with CXCR1 and 2,
chemoattractant for PMNs
Tissue (16) 248 Indicates likely neutrophil allograft
chemotaxis
IL7R 3.4 Cell surface marker for
memory T cells, important
specifically for T cell
development and VDJ
recombination.
N/A 44 Signifies the presence memory T cells









N/A 113 Indicative of ongoing immune
mechanisms
CCL5 3.2 A.k.a. RANTES, chemokine
secreted late after T cell
activation, induced by
IFN-c, secreted by CD8+ T




Tissue (19,21,28–30) 14 Strongly associated with AR and
indicative of Th1 and NK cell
activation
CPA3 3.2 Mast cell carboxypeptidase A,
degrades chymases and
tryptases
N/A 112 Indicates the presence of mast cells in
IFTA and AR, which may be
causative of interstitial fibrosis





N/A 38 Likely parallels immune response to
limit damage by leukocytes,
specifically neutrophils
CORO1A 3.1 Interacts with actin and
involved in a number of
cellular processes such as
cell locomotion,
phagocytosis and NK cell
cytotoxicity. Deficiency in
CORO1 associated with T-
SCID.
Tissue (19) 29 Indicative of ongoing immune
mechanisms
ISG20 3.1 Interferon-induced antiviral
exoribonuclease with
antiviral activity (56)
Tissue (19,21,25,31,32) 22 Induced by IFN-c and strongly
associated with AR
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Gene expression comparison between AR and IFTA
samples
Four gene expression profiles were created by indepen-
dently comparing each histological phenotype (AR, IFTA
with AR, IFTA with inflammation, and IFTA without
inflammation) to the controls (TX). A threshold calcu-
lated FDR of <0.05 and fold change (FC) of >1.2 was
used (full gene lists; Appendix S3). The majority
(72–81%) of DEGs in biopsies with IFTA and histological
evidence of inflammation were common to AR DEGs
(Table 2). Surprisingly, DEGs for IFTA without inflamma-
tion were also highly shared with AR (80%; Figure 2A)
and differentially expressed in a concordant pattern
(Figure 2B). Moreover, 25 of the top 50 IFTA without
inflammation DEGs (ranked by absolute FC) were
shared with the top 50 for AR. A literature review of
the top IFTA without inflammation DEGs showed that
these have been associated with AR in prior studies
(Table 3) (16,19–43). Finally, there was strong enrich-
ment for AR immune/inflammatory and metabolic
molecular pathways using Ingenuity gene set enrich-
ment tools (Table 4).
These findings were then validated using a publically
available gene expression dataset that consisted of 105
“for cause” late biopsies taken between 1 and 31 years
posttransplant (GEO; GSE21374).(16) Using this external
dataset and our thresholds for FDR and FC, we found
that 2523 transcripts (1868 genes) were differentially
expressed in subjects with IFTA (Appendix S4). Subphe-
notypes of IFTA with or without inflammation and IFTA
with AR were not specifically described. Nonetheless,
DEGs in the external dataset were highly shared with
our AR and IFTA biopsy profiles (77%; Figure 2C) and
differentially expressed in the same concordant patterns
(Figure 2D).
Development of “rejection” GCNs
GCNs were created using the DEGs from (1) AR
biopsies, (2) IFTA with AR, and (3) IFTA without AR
samples. Our intent was to identify groups of genes
indicative of discrete acute rejection mechanisms, and
then determine and compare the expression of these
gene groups in IFTA samples. Using a relatively low
coexpression threshold (0.6), a large network of 1825 AR
Table 3. Continued









26 Previously showed to be decreased in
AR (25) and kidney injury, (35) likely
reflects metabolic disturbance. High
coexpression with ALB gene.
REG1A 3.0 Associated with brain and
pancreas regeneration
NA 75 N/A
CD2 3.0 Costimulatory and cell
adhesion molecule on NK
and T cells
Tissue (19,25,31) 24 Strongly associated with AR and
indicative of Th1 and NK cell
activation
CD52 2.9 A.k.a. CAMPATH-1 antigen.
Unknown function on
mature lymphocytes
N/A 17 Indicates presence of mature
lymphocytes
EGF 2.9 Epidermal growth factor Tissue (36) 177 Indicates decreased growth and
proliferation factor, which may
contribute to kidney injury




4 Induced by IFN-c and strongly
associated with AR
CXCL1 2.9 Secreted growth factor that
signals through CXCR2.
Has chemotactic activity for
PMNs.
Tissue (16,38) 99 Similar to CXCL6 above, indicates likely
neutrophil chemotaxis
EVI2B 2.8 N/A N/A 34 N/A




2 Induced by IFN-g and strongly
associated with AR, suggests TCMR




Tissue (20,21,25,28–30) 15 Found in NK and CTLs, strongly
associated with AR and indicative of
TCMR
1For each gene in the interstitial fibrosis and tubular atrophy (IFTA) ranked gene list, the table gives the function and its association
with acute rejection (AR). The third column provides the biological function, and often demonstrates a gene with a role in immune
response and inflammation. The fourth column provides literatures references where the genes are linked to AR in prior studies. The
fifth column gives the ranking in the AR ranked gene list and thus demonstrates that these genes are also some of the most highly
ranked AR genes. FC, fold change; FDR, false discovery rate; N/A, not applicable; PMN, polymorphonuclear leukocytes.
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genes was formed (Appendix S5). “Hub” transcripts, or
“highly connected” genes with the most connections
to other genes in a network, were also determined.
Increasing the stringency of the coexpression threshold in
order to identify smaller, tighter clusters of coex-
pressed genes resulted in three major dense networks
of AR GCNs (Figure 3; Appendix S5). The same proce-
dure applied to the IFTA samples identified the
same three networks as found with the AR
samples, reflecting their highly shared molecular
mechanisms, and this was confirmed in the external
dataset (Appendix S4).
The first network, named AR-GCN1, consisted of only 27
upregulated transcripts, of which 25 were immunoglobulin
(93%). The two remaining genes, TNFRSF17 and FCRL5,
are B cell receptor–associated transcripts critical for
B cell activation. As expected, our biopsies with pathol-
ogy-defined TCMR contain B cells (44). The second net-
work (AR-GCN2) consisted of 190 genes, all upregulated
Table 4: Results of pathway and gene enrichment tool analysis for cAR and IFTA without inflammation differentially expressed tran-
scripts1
cAR IFTA without inflammation
Canonical Pathway Analysis p-value2 Canonical Pathway Analysis p-value2
Communication between innate
and adaptive immune cells
2.00E-13 Granulocyte adhesion and diapedesis 3.16E-12
Allograft rejection signaling 6.31E-12 Antigen presentation pathway 3.98E-12
Antigen presentation pathway 7.94E-11 Allograft rejection signaling 1.51E-09
Dendritic cell maturation 1.23E-10 Dendritic cell maturation 1.51E-09
Graft-versus-host disease signaling 1.38E-10 Agranulocyte adhesion and diapedesis 2.19E-09
FXR/RXR activation 2.29E-09 B cell development 6.91E-09
B cell development 4.90E-09 Role of NFAT in regulation of the
immune response
1.74E-08
LPS/IL-1 mediated inhibition of
RXR function
1.02E-08 Communication between innate and
adaptive immune cells
5.01E-08
OX40 signaling pathway 3.02E-08 OX40 signaling pathway 2.57E-07
Crosstalk between dendritic cells
and natural killer cells
3.02E-08 Complement system 3.55E-06
Activated upstream regulator
analysis2 Activated upstream regulator analysis2
IFN-c 7.22E-79 IFN-c 1.42E-63
TNF 5.00E-66 TNF 5.21E-46
IL-4 1.80E-54 IL-10 1.60E-39
IL-1B 1.77E-48 IL-1B 3.09E-37
IFN-a 1.27E-45 CD40LG 1.62E-34
IL-10 1.60E-43 TGF-B1 1.11E-30
STAT3 7.44E-43 IL-4 1.53E-30
IL-6 1.54E-41 IL-2 1.11E-29
STAT1 1.59E-41 IL-6 1.10E-28
Inhibited upstream regulator
analysis2 Inhibited upstream regulator analysis2
MAPK1 1.31E-28 IL-10RA 8.89E-20
IL-1RN 2.13E-27 PTGER4 7.25E-18
IL-10RA 4.79E-27 IL-1RN 1.52E-16
PPARA 5.83E-21 CD3 8.64E-15
PTGER4 3.75E-20 SOCS1 1.00E-14
TRIM24 2.84E-19 PRDM1 1.66E-13
NKX2-3 5.04E-19 Nr1 h 2.04E-13
PRDM1 2.40E-18 NKX2-3 2.24E-11
cAR, clinical acute rejection; IFN, interferon; IFTA, interstitial fibrosis and tubular atrophy; TNF, tumor necrosis factor.
1Mapping of AR and IFTA without inflammation differentially expressed genes (DEGs) to canonical functional biological pathways was
performed using Ingenuity Pathway Analysis (IPA). Enrichment of these DEGs for immune and biological pathways was performed by
using genes significantly expressed in the kidney as the background. Pathways or genes highlighted in gray are shared between AR
and IFTA without inflammation. These data emphasize the high level of shared immune/inflammatory-based pathways according to
unbiased pathway enrichment tools.
2Benjamini-Hochberg correction applied to p-values account for multiple test comparisons.
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in AR. One hundred eighty-six of these genes (93%) had
known biological functions identifiably related to T cell
immune responses and inflammation (Appendix S6). Fig-
ure 4 illustrates the function and connection of the
AR-GCN1 and AR-GCN2 genes. The illustration includes
107 (56%) of the AR-GCN2 genes. The gene set defining
AR-GCN2 was also independently validated using the
external GEO data.
AR-GCN3 consisted of 186 genes that mapped
functionally to cellular metabolism/tissue integrity
(Appendix S6). Eighty-nine (48%) of these genes were
found to code enzymes important in amino acid turn-
over, glucose and fatty acid metabolism, and energy
production. Twenty-five (13%) coded for proteins
involved in cellular detoxification, and 33 (18%) were
membrane transporters of various important solutes,
organic anions, and drugs. Importantly, all the AR-GCN3
genes are downregulated.
Shared expression of the three key GCNs discovered
in AR patients in the IFTA samples
The geometric means of the AR and IFTA GCN genes
were next determined for all the IFTA phenotypes.
Among the IFTA phenotypes, the geometric mean of
GCN2 transcripts (immune response) was highest in
samples with IFTA and concomitant histological AR
(Figure 5; p = 0.0001 when compared TX). The changes
were second highest in IFTA with inflammation samples,
and lowest in IFTA without inflammation samples. Of
note, the expression in IFTA without inflammation was
still significantly higher than TX (p = 0.003), which
demonstrates the key point of the increased sensitivity
of gene expression profiling to detect an ongoing
immune response and inflammation. The geometric
means of the metabolism/tissue integrity–related
AR-GCN3 genes showed the same hierarchy in the
inverse direction compared to TX controls from the low-
est in IFTA plus AR, higher in IFTA with inflammation,
and highest in IFTA without inflammation (Figure 5).
Thus, metabolic and tissue integrity gene dysregulation
tracks with degrees of inflammation.
Next, we examined the geometric means according to
IFTA grades: Banff 1 (mild), 2 (moderate), and 3 (severe).
The geometric means of GCN1 and GCN2 increase in
relation to both the degree of inflammation and the
severity of IFTA (Figure 6). Likewise, the geometric
mean of GCN3 decreases with both the degree of
inflammation and the extent of IFTA.
IFTA-GCNs correlate with graft loss in biopsies with
IFTA and no inflammation
First, we clustered IFTA samples without inflammation
into sample clusters based on the relative gene
expression of the three IFTA-GCN transcript lists
Figure 3: Gene coexpression networks (GCNs). GCNs were discovered in an unbiased manner using the coexpression of differen-
tially expressed genes for biopsies with clinical acute rejection (AR), interstitial fibrosis and tubular atrophy (IFTA) without AR (i.e. with-
out inflammation), and IFTA with AR (i.e. with inflammation). A number of GCN correlation thresholds (ranging from R2 values of
0.6 to 0.9) were tested to examine both loose and tight networks of coexpressed genes. With an increase in the correlation coeffi-
cient threshold, a large GCN network split into three smaller and tighter clusters with common biological functions for each. Genes
with the most connections (i.e. edges) to other genes in a network are given for each GCN.
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(note: IFTA-GCNs are highly matched to the AR-GCNs).
The heat maps in Figure 7 show that the samples
clearly separate based on the expression of each GCN.
Second, we separated the samples into two clusters
for each GCN: IFTA GCN-high and IFTA GCN-low. We
then compared graft survival for each sample cluster
(Figure 7). Our results show significantly increased rates
of graft loss in patients with IFTA without inflammation
based on IFTA GCN2 (p = 0.02) and GCN3 (p = 0.03).
No correlation to graft loss is seen with GCN1
(p = 0.47). Thus, gene expression profiling detects cor-
relations with graft loss risk for individual patients that
are not detected by histology.
A set of 224 differentially expressed genes
distinguish two groups of IFTA without
inflammation biopsies with higher versus lower risk
of graft loss
In the subset of IFTA patients without inflammation
(n = 40), we determined differential gene expression
between patients with and without graft loss (n = 14 vs.
26; 35% vs. 65%). This analysis revealed 224 differen-
tially expressed transcripts (FDR<0.05) (Appendix S7).
One hundred twenty-five (57%) of these genes were
common to the top-ranked AR DEGs. Many of these
DEGs have been identified in previous studies of acute
and chronic transplant injury associated with graft loss
(e.g. LTF, SERPINA3, CXCL6, MMP7, AFM, ISG20, and
CXCL1; Table 3). Figure 2B and D shows these genes
are also among the most “upregulated” genes in AR.
To determine whether these 224 DEGs could delineate
IFTA without inflammation patients into groups at high
versus low risk of graft loss, we clustered all 40 sam-
ples based on the expression of these 224 transcripts.
Using complete linkage, hierarchical clustering, two
groups were identified with the expected differences in
survival curves (Figure 8). Enrichment of these 224
genes for well-known immune rejection and inflamma-
tion pathways, and the ability of these genes to cluster
our study population into subgroups at high and low risk
graft loss, provides both biological and technical plausi-
bility to their discovery. Next, we validated these results
in an independent, external cohort of “late” biopsies
with IFTA (n = 105) (GEO#: GSE21374). The expression
of these 224 genes was also able to separate this
external cohort into high and low risk phenotypes
(Figure 9).
Figure 4: Biological functions of clinical acute rejection–gene coexpression network 1 (AR-GCN1) and AR-GCN2 genes. The
figure illustrates the biological functions of 107 (56%) of the AR-GCN2 (immune response/inflammation) genes and all 31 of the AR-
GCN1 (B cell/immunoglobulin production) genes. The genes in the illustration with dashed red border are present in the GCNs. It is
important to note that these genes are essentially the same in IFTA-GCN2.
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Given that GCNs 2 and 3 correlate with graft survival, we
examined the overlap of the GCN-defining genes and the
224 graft loss set (Figure 10). The results reveal 188
nonoverlapping genes that refine the GCN classifiers for
graft loss (Appendix S7). Pathway enrichment analysis
(GO) demonstrated the highest correlations with immune
responses (p = 3.2 9 109), cytokine-mediated signaling
(p = 2.8 9 106), interferon gamma (IFN-c) signaling
(p = 1.7 9 105) and antigen presentation via MHC class I
(p = 2.2 9 105) There was no overlap with GCN1 (B cell
genes).
Finally, the majority (n = 84; 71%) of the “for cause”
biopsies and a minority (n = 21; 19%) of the protocol
biopsies had C4d staining performed. Seven hundred
fifty-six genes were differentially expressed between
C4d-stained positive versus negative (Appendix S3).
Seventeen of these 756 genes were shared with the
224 graft loss genes, including two HLA molecules
(HLA-F,-G), three proteasome subunits (PSMB8, 9, 10),
and TAP1—genes that are all in GCN2 (T cell–mediated
immune response) and consistent with activated inter-
feron signaling and antigen presentation. Indeed, path-
way enrichment analysis using gene ontology of the 17
overlapping genes showed the highest correlations with
type I interferon signaling (p = 1.98 9 1011) and antigen
processing and presentation (p = 8.8 9 107). None
were linked mechanistically to B cell networks.
Discussion
In this multicenter, retrospective analysis, we used gene
expression profiles and multiple bioinformatics tools to
show that all the biopsies with IFTA (n = 81) demon-
strate strong molecular evidence of immune rejection,
injury, and decreased metabolism/tissue integrity. This
finding was true for biopsies of IFTA without histological
inflammation (n = 40). In all cases, IFTA was defined by
biopsy histology without identifiable causes present
(i.e. BK nephritis or recurrent disease). We used a novel
bioinformatic method called Gene Coexpression Network
analysis (GCN) to identify the underlying biological net-
works without introducing any user selection bias. A key
point is that the molecular GCNs identified in IFTA were
essentially the same as found for biopsies with AR. The
relative expression of differentially expressed genes
comprising the GCNs correlated with graft loss and the
severity of IFTA based on Banff grades. These findings
indicate that IFTA biopsies, in which there is no other
Figure 5: Using the geometric means for each gene coexpression network (GCN) to rank the impact by phenotype. (A) Geo-
metric means of AR-GCN2 transcripts (immune response/inflammation) correlated with the degree of histological inflammation: clinical
acute rejection (AR) > interstitial fibrosis and tubular atrophy (IFTA) with AR > IFTA with inflammation (IFTA+i) > IFTA without inflam-
mation > transplants with stable function and normal histology (TX). Note that the geometric mean of AR-GCN2 in IFTA without inflam-
mation was still significantly higher than TX (p = 0.003). (B) In contrast, the geometric means of AR-GCN3 transcripts (metabolism/
tissue integrity) were inversely related to inflammation: TX > IFTA without inflammation > AR > IFTA with inflammation > IFTA plus
AR. (C and D) Same analyses using the IFTA-GCNs. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.0001.
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explanation for pathogenesis, demonstrate evidence of
ongoing, cellular immune-mediated injury that is more
sensitively detected with gene expression than by light
histology.
There were several salient findings in the clinical data.
First, patients with a histological diagnosis of AR or
IFTA at any time posttransplant demonstrate decreased
graft survival compared to those with normal biopsies
(TX). Second, our cohorts show 51% of AR and 99% of
“IFTA with AR” samples were diagnosed >1 year
posttransplant. This finding confirms Scientific Registry
for Transplant Recipients and DeKAF data and growing
evidence that AR episodes often occur late posttrans-
plant in both adult (9,45,46) and pediatric populations
(47).
In this study we describe a network of objectively identi-
fied, tightly coexpressed genes with clear biological func-
tion related to T cell–driven immunity and inflammation
(GCN2; Figure 4). The geometric means of these genes
correlated with histologically identified inflammation and
Banff IFTA grades: AR > IFTA with AR > IFTA with
inflammation >IFTA without inflammation (Figures 5 and
6), indicating the increased expression of cellular immune
response genes. A relevant study listed 28 genes that
could most successfully predict AR versus non-AR status
that included biopsies with both antibody-mediated rejec-
tion (ABMR) and TCMR (6). Of these 28 genes, 26
(93%) were found in the top 150 differentially expressed
genes in IFTA without inflammation. Nineteen (68%)
were found in the GCN2s for both AR and IFTA. Several
of these genes, including CXCL9, CXCL11, GZMA, and
CCL5, were the most differentially expressed genes in
IFTA without inflammation (Table 3). Our results are also
consistent with a recent study of 33 kidney biopsies with
“IFTA and inflammation” demonstrating an increase in
the expression of genes associated with both B and
cytotoxic T cells (47). Although we cannot say that the
expression of these genes causes IFTA, our study
demonstrates that graft loss rates and IFTA grades are
associated with higher relative expression of these
genes and this is equally true for the subset of patients
with IFTA without inflammation. Our hypothesis is that
AR and IFTA phenotypes are different stages along the
arc of the same alloimmune process.
Since GCN2 was identified objectively based on gene
coexpression, the comprising genes, particularly those
with a high number of connections to other genes, may
provide new mechanistic and biological understanding of
acute and chronic rejection (Figures 2 and 4). For exam-
ples, dedicator of cytokinesis 2 (DOCK2) is the most con-
nected AR-GCN2 hub gene (Figure 3) and ranked 15 and
10, respectively, in the IFTA-GCN2 hub genes in our data
and the external dataset (Appendix S5). DOCK2 is critical
to lymphocyte homing and the formation of immunologi-
cal synapses. Deficiency of DOCK2 attenuates AR in
mouse cardiac allografts (48). Another AR-GCN2 hub
gene, the IL10RAa, codes for a receptor to the potent
anti-inflammatory cytokine, IL-10. It is also identified in
the IFTA-GCN2s for our data and the external dataset.
IL-10 expression has been associated with acute rejec-
tion (21,25,49) and the overexpression of IL-10 improved
renal function and survival in rat rejection models (31).
IL-10 expression parallels Th1 cytokine expression,
Figure 6: Correlations between biopsy histology, Banff inter-
stitial fibrosis and tubular atrophy (IFTA) grades, and the geo-
metric means of the three IFTA–coexpression networks
(GCNs). The geometric means (y-axis) are plotted as a function of
three interstitial fibrosis and tubular atrophy (IFTA) phenotypes:
IFTA with AR, all IFTA biopsies, and IFTA without inflammation
(IFTA without i) on the z-axis. In parallel, the geometric means are
plotted as a function of Banff IFTA severity grades (x-axis).
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suggesting a protective mechanism limiting the immune
response (50).
In contrast, we demonstrated an inverse relationship
between the metabolism/tissue integrity network (GCN3)
to histological inflammation and IFTA grades, results
consistent with previously published data (35,51). Similar
to GCN2, we revealed that many IFTA samples without
histological inflammation had higher rates of graft loss
correlating with decreased GCN3 gene expression. The
biological function of GCN3 genes may explain the
response to immune-mediated tissue injury. For exam-
ple, PEPD and XPNPEP2 code for enzymes important to
regulating collagen metabolism. Decreased expression of
these genes may contribute to fibrosis. MME encodes
for neutral endopeptidase, a protein that inactivates
several peptide hormones including angiotensin II and
glucagon. Deficiency in MME leads to fetal membranous
glomerulopathy (52). The key point is that therapeutic
targeting of the metabolic/functional impacts of rejec-
tion on tissue integrity may ultimately turn out to be
another effective strategy to preserve graft function and
survival.
Our model is that perpetual T cell–driven immune activation
and inflammation due to ineffective immunosuppression
leads to cell breakdown, release of alloantigens, and the
creation of an inflammatory milieu that promotes T cell–
mediated B cell activation including production of DSAs.
For example, B cell activating factor (TNFSF13B) was
found in the GCN2 while its receptor (TNFRSF17) clus-
tered tightly among the GCN1 genes. The AT-Hook Tran-
scription Factor (AKNA) was found in GCN2, and has
been shown to upregulate transcription of the receptor–
ligand pair CD40 and CD40L, an essential interaction for
B cell activation and antibody isotype switching (53,54).
Another GCN2 gene, SLAMF8, plays a role in B lineage
development and modulation of B cell activation through
B cell receptor signaling (55). Finally, the GCN2 gene,
RANTES (CCL5), is involved in activation of both T and B
cells and immunoglobulin switching in B cells (56).
Consistent with our model, molecular profiling demon-
strates that the relative expression of genes related to
immunoglobulin production (GCN1) did not independently
correlate with graft loss or worse outcomes for either
AR or IFTA phenotypes. However, our model recognizes
the close connections between humoral and T cell immu-
nity. Although ABMR has been associated with IFTA and
increased risk of graft loss (57), the majority of patients
with de novo DSA (dnDSA) followed for 5 years or more
do not lose their grafts (58,59). Other studies demon-
strate that (1) the development of dnDSA correlates with







Figure 7: Graft survival of subjects with IFTA without inflammation according to expression of our three gene coexpression
networks (GCNs). (A) Interstitial fibrosis and tubular atrophy (IFTA) without inflammation samples clustered into two clusters based
on high versus low expression of GCN1 (B cell/immunoglobulin genes). (B) High versus low expression of GCN1 did not demonstrate
a difference in graft survival (p = 0.47). (C and D) In contrast, when this analysis is repeated using GCN2 (immune response/inflammatory),
graft survival of subjects with IFTA without inflammation correlates with relative expression of GCN2 (p = 0.02). (E and F) Relative
expression of GCN3 (metabolism/tissue integrity) also correlates with graft survival (p = 0.03).
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correlate with transplant glomerulopathy but not IFTA,
and (3) biopsies with ABMR frequently show concomi-
tant histological evidence of TCMR (60–63). Our gene
expression and functional mapping are consistent with
this literature by showing a high correlation between C4d
staining and T cell immune networks.
The major limitation in this retrospective, longitudinal
study is that the majority of patients had a single biopsy.
These biopsies only provide a cross-sectional view of
pathology on a large population of transplant patients
with known outcomes. This is not a prospective study
that follows patients from the time of transplantation,
obtains multiple biopsies and gene profiles, and monitors
patient events and other variables over time. Thus,
although our IFTA samples demonstrated strong
evidence for cellular rejection and inflammation at the
time of biopsy, there may have been preceding
nonimmunological insults that also played a role in the
development of IFTA prior to the biopsy. Likewise, we
do not have any data on medication nonadherence. How-
ever, our model is that chronic rejection leads to tissue
injury and IFTA. The corollary is that chronic rejection is
the result of inadequate immunosuppression. Thus,
whether inadequate immunosuppression was the deci-
sion of a physician to reduce dosing or due to patient
medication nonadherence is not relevant to our conclu-
sions. Another limitation is that the overall percentage of
African Americans in this study was less than the per-
centage that receive kidney transplants (10% vs. 34%)
(64). Finally, this study cannot account for the possibility
of ABMR coexisting with TCMR in some biopsies. At the
time this study was designed, dnDSA were not routinely
Figure 8: Graft survival of subjects with IFTA without
inflammation correlates with the expression of 224 differen-
tially expressed “high risk” genes. (A) Interstitial fibrosis and
tubular atrophy (IFTA) without inflammation samples clustered
into high versus low risk clusters based on expression of 224
differentially expressed transcripts. (B) The high versus low risk
sample clusters correlate with graft survival (p = 0.001). DEGs,
differentially expressed genes.
Figure 9: Validating the correlation between high risk gene
expression and graft survival using an independent external
dataset. Interstitial fibrosis and tubular atrophy (IFTA) biopsies
from an external dataset (GEO accession number: GSE21374)
(16) were clustered into high and low risk subgroups based on
expression of the same 224 transcripts that correlated with graft
loss. Again, two subject clusters were identified with marked
difference in survival curves (p = 0.002). Note that the subphe-
notypes of IFTA with and without inflammation were not avail-
able for this external dataset.
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measured except when pathologists found positive C4d
staining. Moreover, the Banff criteria at that time did not
include the current metrics for defining ABMR on
biopsies.
This study demonstrates that IFTA biopsies without alter-
native explanations for pathogenesis (i.e. BK or recurrent
disease) reveal differential gene expression evidence of
ongoing cellular immune-mediated injury. Specifically,
GCNs and the mapping of genes to functional pathways
demonstrate significant molecular overlap to profiles of
AR biopsies, supporting our model that IFTA is a mani-
festation of chronic rejection. The connection between
AR and IFTA profiles is true even for biopsies of IFTA
without inflammation. Expression of GCN2 (immune
response) and GCN3 (metabolism/tissue integrity) genes
correlates with increased risk of graft loss. Furthermore,
a set of 224 genes differentially expressed with graft
loss refines the functional pathways found by GCN analy-
sis. The clinical relevance is that a future prospective trial
may demonstrate that informing immunosuppressive and
monitoring protocols for individual patients based on
serial gene expression profiling of biopsies improves
long-term clinical outcomes.
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